Goetz, Matthew P. http://orcid.org/0000-0002-4383-270X
Okera, Meena
Wildiers, Hans
Campone, Mario
Grischke, Eva-Maria
Manso, Luis
André, Valérie A. M.
Chouaki, Nadia
San Antonio, Belén
Toi, Masakazu
Sledge, George W. Jr.
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 14 September 2020
Accepted: 16 November 2020
First Online: 3 January 2021
Compliance with ethical standards
:
: <i>Funding</i> M.P. Goetz reports research funding from the National Cancer Institute, National Institutes of Health, Department of Defense, Mayo Development, Eli Lilly, Pfizer, Alliance Foundation Trials, Sermonix Pharmaceutical, Translational Breast Cancer Research Consortium, and Minnesota Partnership for Biotechnology and Medical Genomics. H. Wildiers reports consulting fees and honoraria from AstraZeneca, Biocartis, Lilly, Novartis, Pfizer, PUMA Biotechnology, Roche, Sirtex, and Daiiji (all to institution); research grants from Roche and Novartis (all to institution); and travel support from Roche and Pfizer (to H.W). M. Campone received travel support from Pfizer, Novartis, Roche, and AstraZeneca. L. Manso reports consulting fees from Roche, Astra, Novartis, Tesaro, and Pfizer. M. Toi reports research funding from Takeda, Chugai, Pfizer, Taiho, Kyowa-Kirin, Eisai, JBCRG association, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Nippon Kayaku, and AFI technology. G. Sledge Jr. reports research support from Eli Lilly and Company; research support from Pfizer. <i>Financial interests</i> M.P. Goetz reports consulting fees (all to institution) from Eagle Pharmaceuticals, Eli Lilly, Biovica, Novartis, Sermonix, Context Pharm, Pfizer, and Biotheranostics. M. Toi reports consultation fees from Kyowa-Kirin, Daiichi-Sankyo, Konica-Minolta, BMS, Athenex Oncology, and Bertis; and lecture fees from Takeda, Chugai, Eli Lilly Pfizer, Taiho, Kyowa-Kirin, Eisai, Daiichi-Sankyo, MSD, AstraZeneca, Astellas, Shimadzu, Genomic Health, Novartis, Yakult, and Nippon Kayaku. V.A-M. André, N. Chouaki, and B. San Antonio report stocks/shares in Eli Lilly and Company. <i>Non-financial interests</i> M.P. Goetz has consulted for or is/was a board member of NCI Breast Cancer Steering Committee, Translational Breast Cancer Research Consortium, NCCN Breast Cancer Panel, Clinical Pharmacogenetics Implementation Consortium Guide for CYP2D6 and Tamoxifen, NCI SPORE Special Emphasis Panel, and Academic and Community Cancer Research United. M. Campone has consulted for Pierre Fabre Oncology, Sanofi, Novartis, and Servier; speakers’ bureau, Novartis. M. Toi has served on Editorial Boards for Breast Cancer Research and Treatment, Scientific Reports, Frontier Oncology, Cancer Science, International Journal of Clinical Oncology, Asian Journal of Surgery, and International Journal of Biological Markers; and is/was a member of the Board of Directors for Japanese Breast Cancer Research group association, Kyoto Breast Cancer Research network, and Organisation for Oncology and Translational Research. G. Sledge Jr. reports consulting for Syndax, Symphogen, Verseau Therapeutics, and Eli Lilly and Company; Board of Directors for Tessa Therapeutics. <i>Employment</i> V.A-M. André, N. Chouaki, and B. San Antonio are employees of Eli Lilly and Company. M. Okera declares no competing interests. E-M. Grischke declares no competing interests.
: Both studies were reviewed and approved by ethical and institutional review boards. The trials were conducted in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.
: All data generated or analyzed during this study are included in this published article.